Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients with Hypertension

Autor: Thomas G. Wells, Douglas L. Blowey, Reinilde Heyrman, Daniel E. Salazar, Janice E. Sullivan, Joseph R. Sherbotie, SaeHeum Song, Shashank Rohatagi, Jeffrey L. Blumer
Rok vydání: 2012
Předmět:
Zdroj: Pediatric Drugs. 14:401-409
ISSN: 1174-5878
DOI: 10.2165/11631450-000000000-00000
Popis: Background: The prevalence and importance of hypertension in younger patients is becoming increasingly recognized; however, only a limited number of clinical trials have been conducted in the pediatric population. Objective: The aim of this study was to characterize the pharmacokinetics and short-term safety of olmesartan medoxomil in children and adolescents with hypertension. Methods: An open-label, multicenter, single-dose study was conducted in children and adolescents aged 12 months–16 years who were receiving treatment for hypertension or, if not currently treated for hypertension, had either a systolic blood pressure (SBP) or diastolic blood pressure (DBP) ≤95th percentile, or SBP or DBP ≤90th percentile if diabetic or with a family history of hypertension. Patients were stratified by age: 12–23 months (Group 1; none enrolled), 2–5 years (Group 2; n = 4), 6–12 years (Group 3; n = 10), and 13–16 years (Group 4; n = 10). All patients received a single oral dose of olmesartan medoxomil based on the individual’s age and bodyweight. Patients aged
Databáze: OpenAIRE